Sunho Biologics, Inc. (HKG:2898)

Market Cap	1.07B
Revenue (ttm)	40.44K
Net Income (ttm)	-85.10M
Shares Out	150.67M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,400
Average Volume	6,840
Open	6.56
Previous Close	6.72
Day's Range	6.50 - 7.44
52-Week Range	3.00 - 7.40
Beta	n/a
RSI	93.38
Earnings Date	Aug 29, 2025

About Sunho Biologics

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, i...

• Industry: Other
• Founded: 2018
• Employees: 130
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2898

Financial Performance

In 2024, Sunho Biologics's revenue was 38,000, a decrease of -99.78% compared to the previous year's 17.53 million. Losses were -79.97 million, -39.74% less than in 2023.

Financial numbers in CNY